CL2020002967A1 - Formas cristalinas de un inhibidor de tlr7/tlr8 - Google Patents
Formas cristalinas de un inhibidor de tlr7/tlr8Info
- Publication number
- CL2020002967A1 CL2020002967A1 CL2020002967A CL2020002967A CL2020002967A1 CL 2020002967 A1 CL2020002967 A1 CL 2020002967A1 CL 2020002967 A CL2020002967 A CL 2020002967A CL 2020002967 A CL2020002967 A CL 2020002967A CL 2020002967 A1 CL2020002967 A1 CL 2020002967A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline forms
- pyrazolo
- pyridin
- methyl
- tlr7
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- OXDQXRVWDYGAHX-SAVAPUMLSA-N (3S)-N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]morpholine-3-carboxamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1NCCOC1)C OXDQXRVWDYGAHX-SAVAPUMLSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 abstract 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 abstract 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 abstract 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000005987 polymyositis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018087448 | 2018-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002967A1 true CL2020002967A1 (es) | 2021-04-30 |
Family
ID=67145832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002967A CL2020002967A1 (es) | 2018-05-18 | 2020-11-16 | Formas cristalinas de un inhibidor de tlr7/tlr8 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12084460B2 (https=) |
| EP (1) | EP3793998A1 (https=) |
| JP (2) | JP7407740B2 (https=) |
| KR (1) | KR20210013554A (https=) |
| CN (1) | CN112119078A (https=) |
| AR (1) | AR117573A1 (https=) |
| AU (1) | AU2019268583B2 (https=) |
| BR (1) | BR112020022738A2 (https=) |
| CA (1) | CA3097312A1 (https=) |
| CL (1) | CL2020002967A1 (https=) |
| MX (2) | MX2020012259A (https=) |
| TW (2) | TW202417000A (https=) |
| WO (1) | WO2019220390A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| KR20210018818A (ko) | 2018-06-05 | 2021-02-18 | 에프. 호프만-라 로슈 아게 | 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물 |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| WO2020048583A1 (en) | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
| WO2020048595A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| JP7367004B2 (ja) | 2018-09-06 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のピラゾロビリジン化合物 |
| US12421240B2 (en) | 2019-10-31 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| JP2023502087A (ja) | 2019-11-19 | 2023-01-20 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物 |
| JP7649306B2 (ja) | 2019-11-20 | 2025-03-19 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物 |
| WO2022013136A1 (en) | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
| KR20230171469A (ko) | 2021-04-16 | 2023-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| AU2022351495A1 (en) | 2021-09-24 | 2024-02-01 | F. Hoffmann-La Roche Ag | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
| TW202337443A (zh) * | 2022-01-11 | 2023-10-01 | 瑞士商諾華公司 | 使用ｔｌｒ７／８拮抗劑治療ｓｊｏｇｒｅｎ氏症候群或混合性結締組織病之方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2222545A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
| MX2008002207A (es) | 2005-08-16 | 2008-03-27 | Memory Pharm Corp | Inhibidores de fosfodiesterasa 10. |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 다형체 |
| EA037366B1 (ru) | 2015-08-25 | 2021-03-18 | Бейджин, Лтд. | Способ получения ингибитора parp, кристаллические формы и их применения |
| US11998432B2 (en) * | 2016-06-30 | 2024-06-04 | Kimberly-Clark Worldwide, Inc. | Method of manufacturing a foam and fiber composite |
| CR20190119A (es) * | 2016-09-09 | 2019-06-03 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
-
2019
- 2019-05-16 JP JP2020564243A patent/JP7407740B2/ja active Active
- 2019-05-16 TW TW112150642A patent/TW202417000A/zh unknown
- 2019-05-16 CA CA3097312A patent/CA3097312A1/en active Pending
- 2019-05-16 CN CN201980032642.0A patent/CN112119078A/zh active Pending
- 2019-05-16 BR BR112020022738-2A patent/BR112020022738A2/pt unknown
- 2019-05-16 EP EP19735624.9A patent/EP3793998A1/en not_active Withdrawn
- 2019-05-16 AR ARP190101308A patent/AR117573A1/es not_active Application Discontinuation
- 2019-05-16 KR KR1020207032942A patent/KR20210013554A/ko not_active Ceased
- 2019-05-16 US US17/056,351 patent/US12084460B2/en active Active
- 2019-05-16 AU AU2019268583A patent/AU2019268583B2/en not_active Ceased
- 2019-05-16 TW TW108116864A patent/TWI826446B/zh active
- 2019-05-16 MX MX2020012259A patent/MX2020012259A/es unknown
- 2019-05-16 WO PCT/IB2019/054066 patent/WO2019220390A1/en not_active Ceased
-
2020
- 2020-11-13 MX MX2023013584A patent/MX2023013584A/es unknown
- 2020-11-16 CL CL2020002967A patent/CL2020002967A1/es unknown
-
2023
- 2023-12-18 JP JP2023212606A patent/JP2024037930A/ja active Pending
-
2024
- 2024-08-06 US US18/795,371 patent/US20240391938A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202417000A (zh) | 2024-05-01 |
| AR117573A1 (es) | 2021-08-18 |
| JP2021523918A (ja) | 2021-09-09 |
| WO2019220390A1 (en) | 2019-11-21 |
| AU2019268583A1 (en) | 2020-10-29 |
| MX2023013584A (es) | 2023-11-30 |
| US12084460B2 (en) | 2024-09-10 |
| TWI826446B (zh) | 2023-12-21 |
| CA3097312A1 (en) | 2019-11-21 |
| EP3793998A1 (en) | 2021-03-24 |
| MX2020012259A (es) | 2021-01-29 |
| AU2019268583B2 (en) | 2022-01-27 |
| CN112119078A (zh) | 2020-12-22 |
| BR112020022738A2 (pt) | 2021-02-02 |
| JP2024037930A (ja) | 2024-03-19 |
| TW202015698A (zh) | 2020-05-01 |
| JP7407740B2 (ja) | 2024-01-04 |
| US20210206783A1 (en) | 2021-07-08 |
| US20240391938A1 (en) | 2024-11-28 |
| KR20210013554A (ko) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002967A1 (es) | Formas cristalinas de un inhibidor de tlr7/tlr8 | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| ZA201906209B (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| ECSP19024046A (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| PE20121276A1 (es) | Compuestos espirociclicos que contienen nitrogeno y su uso medicinal | |
| AR084659A1 (es) | Metodo para mejorar la resistencia de paneles de yeso | |
| PE20191490A1 (es) | DERIVADOS DE LA PIRIMIDIN ENONA TRICICLICA PARA LA INHIBICION DE RORy Y OTROS USOS | |
| CO2017008809A2 (es) | Compuestos de benzoxaborol y uso de los mismos | |
| GB2573668A (en) | Accelerators for composite cement compositions | |
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| AR047439A1 (es) | Antagonistas del receptor hidroisoindolina taquiquinina | |
| NZ707319A (en) | 5h-pyrrolo[3,2-d]pyrimidin-4-amine compounds and their use in the treatment of allergic diseases and other inflammatory conditions | |
| PE20171104A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| CO2019008385A2 (es) | Mezcla que contiene 3,4-dimetilpirazol y su uso | |
| MX376971B (es) | Formulaciones de concreto ligero | |
| CL2021002667A1 (es) | Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4amina y nuevas sales (divisional solicitud n° 201903468). | |
| CL2013000434A1 (es) | Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia. | |
| AR112457A1 (es) | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona | |
| TWD194380S (zh) | Container (2) | |
| CL2021000254A1 (es) | Formas cristalinas de un inhibidor de lta4h | |
| MY173476A (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| CN103637922A (zh) | 一种中药皮肤消毒湿巾 | |
| CN103637923A (zh) | 一种皮肤消毒湿巾 |